Core Insights - Corbus Pharmaceuticals Holdings, Inc. announced participation in several upcoming investor conferences, highlighting its commitment to engaging with the investment community [1][2][3] Company Overview - Corbus Pharmaceuticals is focused on oncology and obesity, with a diversified portfolio aimed at addressing serious illnesses through innovative scientific approaches [3] - The company's pipeline includes: - CRB-701: A next-generation antibody drug conjugate targeting Nectin-4 on cancer cells [3] - CRB-601: An anti-integrin monoclonal antibody that blocks TGFβ activation on cancer cells [3] - CRB-913: A peripherally restricted CB1 inverse agonist for obesity treatment [3] - Corbus is headquartered in Norwood, Massachusetts [3] Upcoming Conferences - B. Riley Securities Precision Oncology & Radiopharma Investor Conference on February 28, 2025, featuring a panel on Nectin-4 targeting therapies [2] - TD Cowen 45 Annual Health Care Conference on March 4, 2025, with a presentation scheduled [2] - Wedbush Securities Cardiometabolic Conference on March 10, 2025, focusing on alternative obesity targets [2] - Leerink Partners Global Healthcare Conference on March 12, 2025, including a presentation [3] - BMO 2025 Obesity Summit on March 25, 2025, discussing emerging technologies [3]

Core Insights - Corbus Pharmaceuticals announced the presentation of data from its first-in-human dose escalation clinical study of CRB-701 at the 2025 ASCO GU symposium [1][2] - The study focuses on a next-generation antibody-drug conjugate targeting Nectin-4 in patients with metastatic urothelial cancer and other solid tumors [3][9] Study Overview - The Phase 1 Western study enrolled participants with metastatic urothelial cancer and other solid tumors associated with Nectin-4 expression, with enrollment completed in October 2024 [3] - A total of 38 participants were enrolled, with 26 evaluable for efficacy at the December 2024 data cut [3][5] - The study mirrored the top four dose cohorts used in a concurrent China study, utilizing doses of 1.8, 2.7, 3.6, and 4.5 mg/kg [3][6] Safety and Efficacy Data - CRB-701 demonstrated a favorable safety profile, with no dose-limiting toxicities observed in either the Western or China studies [6][7] - Peripheral neuropathy rates were low, with 5% in the Western study and 3% in the China study, while skin disorders were reported at 24% in the Western study compared to 8% in the China study [7] - Clinical responses were observed in multiple tumor types, including cervical cancer and head and neck squamous cell carcinoma, with notable efficacy signals [6][8][13] Future Development - The dose optimization phase has commenced, focusing on 2.7 mg/kg and 3.6 mg/kg cohorts for various tumor types [8] - The study's findings support the continued clinical development of CRB-701, particularly for tumor types expressing Nectin-4 [8][9]

Core Insights - Corbus Pharmaceuticals announced the release of an abstract for its first-in-human dose escalation clinical study of CRB-701, which will be presented at the 2025 ASCO GU Symposium [1][2] - The study involves 31 patients as of September 2024, with updated data on 38 patients as of December 2024 to be presented [1] - The three-part Phase 1 Western study is evaluating the safety, pharmacokinetics, and efficacy of CRB-701 in patients with advanced solid tumors expressing high levels of Nectin-4 [3] Company Overview - Corbus Pharmaceuticals is focused on oncology and obesity, with a diverse portfolio aimed at addressing serious illnesses through innovative scientific approaches [5] - The company's pipeline includes CRB-701, an antibody-drug conjugate targeting Nectin-4, CRB-601, an anti-integrin monoclonal antibody, and CRB-913, a CB1 receptor inverse agonist for obesity treatment [5] - Corbus is headquartered in Norwood, Massachusetts, and engages with the public through various social media platforms [5]

Core Insights - Corbus Pharmaceuticals announced data from its first-in-human dose escalation clinical study of CRB-701, which will be presented at the 2025 ASCO GU Symposium in San Francisco from February 13-15, 2025 [1] - The study focuses on CRB-701, a next-generation antibody-drug conjugate targeting Nectin-4 in patients with advanced solid tumors [4][5] Study Details - The Phase 1 study (NCT06265727) consists of three parts: Part A (dose escalation), Part B (dose optimization), and Part C (dose expansion) [3] - Part A evaluated four doses: 1.8 mg/kg, 2.7 mg/kg, 3.6 mg/kg, and 4.5 mg/kg administered every three weeks [3] Product Information - CRB-701 (SYS6002) is designed to target Nectin-4, a clinically validated tumor-associated antigen in urothelial cancer, using a site-specific, cleavable linker and a homogeneous drug-antibody ratio of 2 with MMAE as the payload [4] - Corbus has a diversified portfolio that includes CRB-601, an anti-integrin monoclonal antibody, and CRB-913, a CB1 receptor inverse agonist for obesity treatment [5]

Core Insights - Corbus Pharmaceuticals Holdings, Inc. will participate in the 43rd Annual J.P. Morgan Healthcare Conference from January 13-16, 2025, with CEO Yuval Cohen presenting and attending investor meetings [1][2] Company Overview - Corbus Pharmaceuticals is focused on oncology and obesity, with a diversified portfolio aimed at addressing serious illnesses through innovative scientific approaches [3] - The company's pipeline includes: - CRB-701: A next-generation antibody drug conjugate targeting Nectin-4 on cancer cells [3] - CRB-601: An anti-integrin monoclonal antibody that blocks TGFβ activation on cancer cells [3] - CRB-913: A highly peripherally restricted CB1 receptor inverse agonist for obesity treatment [3] - Corbus is headquartered in Norwood, Massachusetts [3]

Financial Performance - Corbus Pharmaceuticals reported a net loss of approximately $13.8 million for the three months ended September 30, 2024, compared to a net loss of $10.1 million for the same period in 2023, reflecting an increase in losses of about 36.6%[91]. - Total operating expenses for the three months ended September 30, 2024, were approximately $15.5 million, a 63% increase from $9.5 million in the same period of 2023[95]. - The company has an accumulated deficit of approximately $467.4 million as of September 30, 2024[91]. - Other income (expense), net for the three months ended September 30, 2024 was approximately $1.7 million in income, compared to an expense of approximately $0.6 million for the same period in 2023, reflecting a change of $2.3 million[98]. Research and Development - Research and development expenses increased to approximately $10.8 million for the three months ended September 30, 2024, up 65% from $6.6 million in the prior year, primarily due to costs associated with CRB-701 clinical trials[95]. - Research and development expenses for the nine months ended September 30, 2024 totaled approximately $23.4 million, a decrease of $0.8 million from approximately $24.2 million for the same period in 2023, primarily due to decreases in licensing costs[99]. - CRB-701 demonstrated an overall response rate of 44% and a disease control rate of 78% in metastatic urothelial cancer during clinical trials[86]. - CRB-913 is expected to enter Phase 1 studies in the first quarter of 2025, following IND-enabling studies[87]. General and Administrative Expenses - General and administrative expenses rose to approximately $4.7 million for the three months ended September 30, 2024, a 60% increase from $2.9 million in the same period of 2023[97]. - General and administrative expenses for the nine months ended September 30, 2024 totaled approximately $12.7 million, an increase of $1.9 million from approximately $10.8 million for the same period in 2023, driven by higher stock-based compensation costs[101]. Cash Flow and Financing - Net cash used in operating activities for the nine months ended September 30, 2024 was approximately $30.9 million, which includes a net loss of approximately $30.7 million[105]. - Cash used by investing activities for the nine months ended September 30, 2024 totaled approximately $130.0 million, primarily related to purchases of investments[106]. - Cash provided by financing activities for the nine months ended September 30, 2024 totaled approximately $166.6 million, related to the issuance of common stock[107]. - The company expects its cash, cash equivalents, and investments of approximately $159.4 million at September 30, 2024 will be sufficient to meet its operating and capital requirements through the third quarter of 2027[108]. - The company will need to raise significant additional capital to continue funding clinical trials for CRB-701, CRB-601, and CRB-913[109]. Debt and Agreements - The loan from K2 HealthVentures LLC was fully paid off with a final payment of $11.8 million on August 1, 2024[90]. - The CSPC License Agreement will remain effective on a Licensed Product until the expiration of the Royalty Term, which is determined by the later of the expiration of the last-to-expire Valid Claim, 10 years after the First Commercial Sale, or expiration of Regulatory Exclusivity[118]. - The Royalty Term begins from the First Commercial Sale of the Licensed Product in the country[118]. - The CSPC License Agreement may be terminated earlier for material breach, advance notice by Corbus, or upon a party's bankruptcy[118].

Financial Performance - Corbus Pharmaceuticals reported a net loss of approximately $13.8 million, or $1.15 per diluted share, for Q3 2024, compared to a net loss of approximately $10.1 million, or $2.27 per diluted share for the same period in 2023[9]. - The total operating loss for Q3 2024 was approximately $15.5 million, compared to $9.5 million in the same period in 2023[10]. - The total stockholders' equity increased to $150.5 million as of September 30, 2024, compared to a deficit of $6.9 million at the end of 2023[20]. Operating Expenses - Operating expenses increased by $6.0 million to approximately $15.5 million for Q3 2024, primarily due to a $3.2 million increase in CRB-701 clinical trial costs and higher compensation costs of $1.6 million[10]. Clinical Trials and Data - The company completed enrollment of the dose escalation part of the Phase 1 clinical trial of CRB-701, with first data expected in Q1 2025, showing a 44% overall response rate (ORR) in metastatic urothelial cancer and 43% in cervical cancer at doses ≥ 1.2 mg/Kg[4]. - CRB-913 pre-clinical data presented at Obesity Week 2024 indicated a dose-response achieving up to 38% weight loss in diet-induced obesity mice, with levels in the brain being 15-fold lower than monlunabant[6]. - The company presented promising efficacy and safety data for CRB-701 at ASCO 2024, indicating the drug is clinically active with a differentiated safety profile[2]. - CRB-601, a monoclonal antibody, is expected to dose the first patient in Q4 2024 for the treatment of advanced solid tumors[8]. Cash and Funding - As of September 30, 2024, the company had $159.4 million in cash, cash equivalents, and investments, expected to fund operations through Q3 2027[11]. - The company raised $35.6 million in net proceeds during Q3 2024 through its ATM program by issuing 663,730 shares[11].

Core Viewpoint - Corbus Pharmaceuticals Holdings, Inc. will participate in the Guggenheim Securities Healthcare Innovation Conference, highlighting its commitment to innovative treatments in oncology and obesity [1][2]. Company Overview - Corbus Pharmaceuticals is focused on oncology and obesity, with a diversified portfolio aimed at addressing serious illnesses through innovative scientific approaches [2]. - The company's pipeline includes: - CRB-701: A next-generation antibody drug conjugate targeting Nectin-4 on cancer cells [2]. - CRB-601: An anti-integrin monoclonal antibody that blocks TGFβ activation on cancer cells [2]. - CRB-913: A peripherally restricted CB1 receptor inverse agonist for obesity treatment [2]. - Corbus is headquartered in Norwood, Massachusetts [2]. Event Details - The Guggenheim Securities Healthcare Innovation Conference will take place from November 11-13, 2024, with a specific fireside chat and one-on-one investor meetings scheduled for November 12, 2024, at 10:00 a.m. ET [1][2].

Group 1 - Corbus Pharmaceuticals (CRBP) closed at $59.70, with a 2.8% gain over the past four weeks, and a mean price target of $85.86 suggests a 43.8% upside potential [1] - The average price targets from analysts range from a low of $76 to a high of $105, with a standard deviation of $9.30, indicating variability in estimates [2] - Analysts have shown increasing optimism regarding CRBP's earnings prospects, with a strong agreement in revising EPS estimates higher, which correlates with potential stock price movements [9][10] Group 2 - The Zacks Consensus Estimate for CRBP has increased by 25.3% due to three estimates moving higher in the last 30 days [10] - CRBP holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [11] - While the consensus price target may not be a reliable indicator of the stock's potential gain, it does provide a directional guide for price movement [11]

NORWOOD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), today announced the appointment of Winston Kung to its Board of Directors. The appointment was effective as of August 16, 2024. Mr. Kung will also chair the Audit Committee. "With this track record of success in both the pharma industry and on Wall Street, Winston has earned a welldeserved reputation for his leadership and financial acumen," said Alan F. Holmer, Chairman of the ...